The authors reviewed 11 randomized trials in which 328 patients were randomized to either receive or not receive fibrin sealant treatment after breast cancer surgery. End points included seroma ...

Fibriant’s lead product, RecoSeel, is the first fully recombinant fibrin sealant for use as a biodegradable and bioactive topical haemostat to stop excessive bleeding during surgery. It is based ...